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Abstract
Introduction PARP-1 (polyADP-ribose polymerase-1) is known
to be activated in response to DNA damage, and activated
PARP-1 promotes DNA repair. However, a recently disclosed
alternative mechanism of PARP-1 activation by phosphorylated
externally regulated kinase (ERK) implicates PARP-1 in a vast
number of signal-transduction networks in the cell. Here, PARP-
1 activation was examined for its possible effects on cell
proliferation in both normal and malignant cells.
Methods In vitro (cell cultures) and in vivo (xenotransplants)
experiments were performed.
Results Phenanthridine-derived PARP inhibitors interfered with
cell proliferation by causing G2/M arrest in both normal (human
epithelial cells MCF10A and mouse embryonic fibroblasts) and
human breast cancer cells MCF-7 and MDA231. However,
whereas the normal cells were only transiently arrested, G2/M
arrest in the malignant breast cancer cells was permanent and
was accompanied by a massive cell death. In accordance,
treatment with a phenanthridine-derived PARP inhibitor
prevented the development of MCF-7 and MDA231
xenotransplants in female nude mice. Quiescent cells (neurons
and cardiomyocytes) are not impaired by these PARP inhibitors.
Conclusions These results outline a new therapeutic approach
for a selective eradication of abundant nonhereditary human
breast cancers.
Introduction
PolyADP-ribose polymerases (PARPs) catalyze a posttransla-
tional and energy-consuming modification of proteins by poly-
ADP-ribosylation. This enzymatic reaction is initiated by ADP-
ribose transferase activity, which proceeds with polymerization
of ADP-riboses into long and branched polymers [1]. In the
chromatin, polyADP-ribosylation apparently regulates the
interaction of PARPs and their substrates with protein part-
ners and DNA. PARP-1 is a highly conserved DNA-binding
protein and the most abundant nuclear PARP. The enzyme is
known to be activated in response to DNA single-strand
breaks [1], and its activation induces chromatin remodeling,
rendering the DNA more accessible to transcription factors
and repair enzymes [1,2].
Our recent findings in quiescent cells and in cell-free systems
disclosed an alternative mechanism, inducing an intense and
long-lasting activation of PARP-1 in the absence of DNA dam-
age [3,4]. In this process, PARP-1 interaction with phosphor-
ylated ERK2 (externally regulated kinase) resulted in PARP-1
activation and polyADP-ribosylation in a positive-feedback
mechanism that kept PARP-1 polyADP-ribosylated as long as
ERK2 was phosphorylated [3]. In addition, polyADP-ribo-
sylated PARP-1 highly augmented the activity of
ERK: externally regulated kinase; MEK: mitogen-activated protein kinase kinase; PARP: polyADP-ribose polymerase; PTEN: phosphatase and tensin 
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phosphorylated ERK, enhancing phosphorylation of ERK-tar-
geted transcription factors, core histone acetylation, and the
expression of ERK target genes, some of which are onco-
genes [3-6]. Because ERK activity in the nucleus is a key mod-
ulator for inducing proliferation versus differentiation in a
variety of cancer cells [7,8], these findings suggest that PARP-
1 activation might be a possible target for mechanisms induc-
ing cell proliferation.
PARP inhibitors were designed to prevent PARP-1 activation
in response to nicked DNA, in an attempt to suppress PARP
mediated DNA repair [9-12]. Several generations of PARP
inhibitors were designed to prevent PARP-1 activity by block-
ing the binding of the nicotinamide moiety of NAD+ in the cat-
alytic site of the enzyme. PARP inhibitors differ in their
chemical structure, their potency, stability, solubility in water,
and apparently even in their therapeutic potential [9-12]. Sev-
eral groups of PARP inhibitors (including phenanthridine deriv-
atives) were designed to protect cells under stress conditions
from cell death induced by a massive activation of PARP-1 (for
example, stroke, inflammation; [10,12]), or to cause cell death
in malignant cells by preventing polyADP-ribosylation-depend-
ent DNA repair [9,11]. In accordance with this concept, PARP
inhibitors were tested for their therapeutic potential in malig-
nant cells with impaired DNA-repair machinery [13,14] (bear-
ing mutations in the tumor-suppressor genes BRCA1  and
BRCA2 that cause an impaired DNA repair [15]) or in combi-
nation with DNA-damaging treatments [11]. However, in view
of findings indicating that activated PARP-1 highly augments
the activity of ERK in the nucleus even in the absence of DNA
damage [3,4], a different therapeutic potential of PARP inhib-
itors is examined in breast cancer cells lacking BRCA
mutations.
Materials and methods
Human breast cancer cell line MCF-7 and MDA231 and
human epithelial cells MCF-10A were supplied by ATCC Co.
(American Type Culture Collection, P.O. Box 1549, Manas-
sas, VA 20108, USA. The dealer in Israel is Almog Diagnostic
& Medical equipment Ltd.). Mouse embryonic fibroblasts were
prepared in the laboratory of Dr. Dantzer (Strasbourg, France).
MCF-7 and MDA231 cells were cultured in six-well multidish
plates (Nunc, Thermo Fisher scientific, Reskilde, Denmark).
MCF-7 and MDA231 cells were maintained in a medium con-
taining DMEM (cat. 01055-1A), 10% Fetal bovine serum
(FBS; cat. 04-124-1A), 1% L-glutamine (cat. 03-020-1B), and
1% Pen-Strep Ampho (cat. 03-033-1B) (Gibco, purchased
from Rhenium, Rehovot, Israel).
MCF-10A human epithelial cells were cultured in DMEM/F12
(Gibco) with FBS (Gibco) 6%, EGF (100 μg/ml, Cytolab,
Rehovot, Israel) 0.02%, hydrocortisone (50 μM, Sigma) 2.8%,
insulin (10 mg/ml, Sigma) 0.1%, and Pen/Strep (Gibco) 1%.
Mouse embryonic fibroblasts were cultured in a medium con-
taining DMEM (cat. 01055-1A), 10% FBS (cat. 04-121-1A),
1% L-glutamine (cat. 03-020-1B), and 1% Pen-Strep Ampho
(cat. 03-033-1B) (Gibco, purchased from Rhenium, Rehovot,
Israel).
Phenanthridine-derived PARP inhibitors
We examined the effect of phenanthridine-derived com-
pounds that act as potent PARP inhibitors. These included PJ-
34, (N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N, N-dimethyl-
acetamide), Tiq-A, (4H-thieno [2,3-c]isoquinolin-5-one) and
Phen, (6(5H) phenanthridinone). PJ-34 and Phen were pur-
chased from Alexis Biochemicals (Alexis Corporation,
Lausanne, Switzerland). Tiq-A was purchased from Sigma,
Israel. Their chemical structure is presented in Figure 1.
The effect of PJ-34 on the development of MCF-7 and 
MDA231 xenotransplants
Xenotransplants were developed in female CD-1 nu/nu mice
5 to 6 weeks old (Charles River Labs, Sulzfeld, Germany) pur-
chased in Israel from Harlan Labs, Jerusalem. MCF-7 and
MDA231 cells were injected subcutaneously, about 107 MCF-
7 or MDA231 cells in 150 μl of PBS and 150 μl of Matrigel
Basement Membrane Matrix (Becton Dickinson, Bedford, MA,
USA; In Israel, Bactolab Diagnostics). In mice treated with PJ-
34, Injection was adjacent to subcutaneous osmotic pumps
dripping PJ-34 by a slow release. The mice were maintained
under specific pathogen-free conditions with access to mouse
chow and water ad libitum. PJ-34 (2 mM dissolved in 100 μl
PBS) was inserted in subcutaneously implanted Alzet osmotic
pumps, designed to release PJ-34 continuously (at about 0.6
nmol/h) for 14 days. For comparison, in the in vitro experi-
ments, the amount of PJ-34 per dish was approximately 20
nmol. Subcutaneous implantation of these pumps was per-
formed before injection by a veterinarian (Dr. Kastel David). All
the experiments with nude mice conform with the Guide for
the Care and Use of Laboratory Animals published by the NIH
(publication No. 85-23, revised 1996). Approval was granted
by the Israeli Ministry of Health ethics review board in the Tel-
Aviv University (M08033).
Figure 1
The chemical structures of the PARP inhibitors PJ-34, Tiq-A, and Phen The chemical structures of the PARP inhibitors PJ-34, Tiq-A, and Phen.Available online http://breast-cancer-research.com/content/11/6/R78
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Cell survival in cells treated with PJ-34
MCF-7 or MDA231 cells (seeded about 500,000 cells/3-mm
well in six-well plates) were treated with PJ-34 applied only
once, 24 hours after seeding. In some experiments, cells were
reseeded in PJ-34-free medium in 10-cm plates for colony for-
mation. In these experiments, after 2 weeks of incubation with-
out application of PJ-34, cells were fixed (methanol/acetic
acid, 3:1), stained with crystal violet, and counted to determine
cell survival.
Flow cytometry was used to monitor changes in the ploidy
level of malignant and normal cells labeled with propidium
Iodide (PI) staining. Counting the cells with flow cytometry in
selected time periods for several hours, indicated changes in
their cell cycle caused by treatment with PJ-34. Flow cytome-
try was performed by using a Becton Dickenson machine and
the FlowJo software (Tree Star, Ashland, OR, USA). Untreated
cells were used as controls for each cell type.
Results
Phenanthridine-derived PARP inhibitors efficiently 
eradicated MCF-7 and MDA231 breast cancer cells 
without impairing human epithelial MCF-10A or mouse 
embryonic fibroblasts
We examined the effect of PARP inhibitors on MCF-7 and
MDA231 human breast cancer cells. Cells were treated with
the potent PARP inhibitors, PJ-34, Tiq-A, and Phen (Figure 1)
applied only once, 24 hours after seeding. MCF-7 cells did not
survive after 48 to 72 hours of incubation with 10 μM PJ-34
(Figure 2a), nor after incubation with Tiq-A (100 μM) or Phen
(50 μM) (Figure 2a). At these concentrations, PJ-34, Tiq-A,
and Phen inhibit the activity of PARP-1 [3,10,16,17]. Signifi-
cant cell death was observed even at lower concentrations of
PJ-34 (Figure 2b). More than 99% of MCF-7 cells were erad-
icated after 48 hours of incubation with 10 μM PJ-34 (Figure
2b). The damage was irreversible. No recovery was observed
in MCF-7 cells treated with PJ-34 for 48 to 72 hours and then
reseeded in PJ-34-free medium and incubated for 2 additional
weeks in the absence of PJ-34 (Figure 2c). Massive cell death
also was observed in MDA231 incubated for 72 to 96 hours
with PJ-34 applied only once, 24 hours after seeding. These
cells were completely eradicated by incubation with 20-30 μM
PJ-34 (Figure 2d). No recovery was observed in MDA231
cells incubated with 30 μM PJ-34 for 72 hours, after reseeding
in PJ-34-free medium and incubation for 2 additional weeks.
Flow cytometry disclosed G2/M arrest and cell death in both
MCF-7 and MDA231 cells. G2/M arrest was already observed
in both cell types 6 hours after treatment with 10 μM PJ-34. It
was not relieved within 120 hours of the experiment and was
accompanied by massive cell death (Figure 3).
Normal dividing cells, human epithelial cells MCF-10A (Figure
4a), were similarly arrested at G2/M (Figure 4b). Their arrest
also was detected 6 hours after application of PJ-34 (10 μM).
However, unlike the malignant cells, MCF10A cells were only
temporarily arrested (no arrest observed after 18 hours of
incubation with PJ-34), and this transient arrest was not
accompanied by cell death (Figure 4a and 4b). MCF-10A cells
overcame the cell-cycle arrest, and continued to proliferate as
normal cells, even when incubated with the same concentra-
tions of PJ-34 and for the same durations used to eradicate
MDA231 cells (compare Figures 2d and 4a). Also, prolifera-
tion of MCF-10A cells was not significantly reduced, even after
a long incubation of 14 days with 10 μM PJ-34 (Figure 4a).
G2/M cell-cycle arrest also was detected in mouse embryonic
fibroblasts (Figure 5a) after 6 hours of incubation with PJ-34
(10 μM) (Figure 5b). These cells also overcame the cell-cycle
arrest, and the arrest in cell cycle was not accompanied by cell
death (Figure 5b).
Thus, treatment with PJ-34 induced a transient G2/M arrest in
these normal proliferating cells, which was not accompanied
by cell death (Figures 4 and 5), whereas the cell cycle of malig-
nant cells MCF-7 and MDA231 was permanently arrested,
and these cells were eradicated by incubation with PJ-34
applied only once 24 hours after seeding (Figures 2 and 3). An
efficient eradication of MCF-7 cells was observed after 48
hours of incubation with 10 μM PJ-34, whereas MDA231 cells
were massively eradicated only after 72 hours of incubation
with PJ-34, 20-30 μM. Quiescent cells, brain cortical neurons,
and cardiomyocytes were not impaired by incubation with the
examined phenanthridine-derived PARP inhibitors (10 to 20
μM PJ-34, 100 μM Tiq-A, and 50 μM Phen [3,10,16,17]).
PJ-34 prevented the development of MCF-7 and MDA231 
xenotransplants in nude female mice
In vivo experiments were carried out in nude female mice (nu/
nu) injected subcutaneously with MCF-7 or MDA231 cells
(Figure 6 and Additional data file 1). To test the effect of PJ-34
on the development of xenotransplants in the injected mice,
PJ-34 (2 mM dissolved in 100 μl PBS) was inserted into sub-
cutaneously implanted osmotic pumps (Alzet) that enable its
constant slow release for 14 days (Methods). In the control
nude mice, pumps contained only PBS, or pumps were not
implanted. On the next day, 24 hours after pump implantation,
each mouse was injected subcutaneously with approximately
107 MCF-7 or MDA231 cells dispersed in Matrigel (Methods).
Tumors developed within 6 to 7 weeks in the control mice
injected with MCF-7 cells and within 10 days in the control
mice injected with MDA231 cells. One mouse died 3 weeks
after being injected with MDA231 cells. In contrast, no visible
tumors developed in the PJ-34-treated mice during 4 months
after injection of MCF-7 cells and during the 10 weeks after
injection with MDA231 cells (Figure 6a and 6b and Additional
data file 1). Importantly, the 14-day treatment with a slow
release of PJ-34 did not affect the vitality, growth, develop-
ment, or any other behavior of the treated mice during the fol-
low-up periods.Breast Cancer Research    Vol 11 No 6    Inbar-Rozensal et al.
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Figure 2
Eradication of MCF-7 and MDA231 human breast cancer cells by phenanthridine-derived PARP inhibitors Eradication of MCF-7 and MDA231 human breast cancer cells by phenanthridine-derived PARP inhibitors. (a) MCF-7 cells were seeded (about 
500,000/well) in six-well plates and incubated for 48 hours with the potent PARP inhibitors, PJ-34 (10 μM), Tiq-A (50 μM), and Phen (25 μM), each 
applied (a single application) 24 hours after seeding. Cells were counted and pictured under a microscope (0.02 to 0.03 mm2 per field). Control 
(upper left) and treated MCF-7 cells are presented, 72 hours after seeding. These representative results were repeated in five different experiments. 
(b) Survival rate (percentage relative to untreated cells at each time point, control) of MCF-7 breast cancer cells after incubation for 48 hours with 
several concentrations of PJ-34, applied (a single application) 24 hours after seeding. Each value represents the average value of five measurements 
in different cell cultures. (c) Colony formation (percentage relative to colony formation of untreated cells) of MCF-7 breast cancer cells reseeded and 
incubated for 2 additional weeks in the absence of PJ-34, 48 hours after a single application of PJ-34 at several concentrations was applied 24 
hours after the initial seeding (Methods). Each value represents the average value of three measurements in three different experiments. (d) Left 
panel: MDA231 breast cancer cells were seeded (about 500,000/well) in six-well plates. PJ-34 was applied into the medium at the indicated final 
concentrations 24 hours after seeding. Cells were counted and pictured under microscope (0.02 to 0.03 mm2 per field). Right panel: Survival rate 
(percentage relative to untreated cells at each time point, control) of MDA231 breast cancer cells after 72 hours of incubation with several concen-
trations of PJ-34, applied (a single application) 24 hours after seeding. Each value is an average of three measurements obtained in three different 
experiments.Available online http://breast-cancer-research.com/content/11/6/R78
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Figure 3
G2/M arrest and cell death in MCF-7 and MDA231 treated with PJ-34 G2/M arrest and cell death in MCF-7 and MDA231 treated with PJ-34. The effect of PJ-34 on the cell cycle was examined with flow cytometry. PJ-34 
(10 μM) was applied to both types of cells, 24 hours after seeding. Controls: Untreated MCF-7 48 hours after seeding and untreated MDA231 cells 
72 hours after seeding. At the indicated time, cells were collected, permeabilized (75% ethanol in DDW), and stained with propidium iodide (PI). The 
effects of PJ-34 on cell eradication and the kinetics of S-phase entry and G2/M transition were evaluated by the percentages of cells at these 
phases. G2/M arrest accompanied by cell death was detected in both cell types after 6 hours of incubation with PJ-34. Similar results for both cell 
types were obtained in three different experiments.Breast Cancer Research    Vol 11 No 6    Inbar-Rozensal et al.
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Figure 4
PJ-34 did not eradicate normal human epithelial cells MCF-10A PJ-34 did not eradicate normal human epithelial cells MCF-10A. (a) MCF-10A cells were seeded (about 500,000/well) in six-well plates (Methods). 
PJ-34 was applied once at the indicated concentrations to MCF-10A cells 24 hours after seeding. Untreated MCF-10A cells and MCF-10 cells incu-
bated with 10, 20, and 30 μM PJ-34 for 72 hours, and MCF-10A cells incubated with 10 μM PJ-34 for 2 weeks, were pictured under a microscope. 
These representative results were observed in three different experiments. (b) MCF-10A cells overcame G2/M arrest induced by treatment with PJ-
34 (10 μM). Cells were analyzed with flow cytometry at the indicated periods after addition of 10 μM PJ-34. G2/M arrest detected 6 hours after PJ-
34 application was relieved after 18 hours. Control represents untreated MCF-10A cells 72 hours after seeding. Similar results were measured in 
three different experiments.Available online http://breast-cancer-research.com/content/11/6/R78
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Figure 5
PJ-34 did not eradicate mouse embryonic fibroblasts PJ-34 did not eradicate mouse embryonic fibroblasts. (a) The effect of PJ-34 on mouse embryonic fibroblasts (MEF) was measured after repeated 
applications of PJ-34 (10 μM) 24 hours and 72 hours after seeding, as indicated. MEF, untreated and incubated with PJ-34 (10 μM) for 48 hours, 
and MEF, untreated and incubated with 20 μM PJ-34 for 100 hours are shown. On the right are displayed cell counts (0.02 to 0.03 mm2 per field) of 
cells incubated with PJ-34 (10 μM, after the first application, and 20 μM, after the second application) for the indicated time periods. Each value is 
an average value of cells counted in five different experiments. (b) MEFs were analyzed with flow cytometry at the indicated periods after addition of 
PJ-34. A transient G2/M transition arrest is indicated in MEFs incubated for 6 hours with PJ-34 (10 μM). Control: Untreated MEFs 48 hours after 
seeding. Similar results were obtained in three different experiments.Breast Cancer Research    Vol 11 No 6    Inbar-Rozensal et al.
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Figure 6
Treatment with PJ-34 prevented the development of MCF-7 and MDA231 xenotransplants Treatment with PJ-34 prevented the development of MCF-7 and MDA231 xenotransplants. (a) Xenotransplants of MCF-7 developed within 6 to 7 
weeks in three mice that were not treated with PJ-34 (control mice; tumors are indicated by arrows; left). Tumors did not develop in any of the three 
mice treated with PJ-34 for 14 days by a slow release of PJ-34 from a subcutaneously implanted osmotic pump (Alzet; pump ￿; Methods) (Right). 
Tumors were not detected during 4 months after injection with the MCF-7 cells. Each female CD-1 nu/nu mouse was injected with about 107 MCF-
7 cells collected from 80% to 90% confluent cell cultures. Cells were immersed in Matrigel/PBS (Methods). Cells were injected near the pump, one 
hour after pump implantation. (b) Each CD-1 nu/nu female mouse was injected with about 107 MDA231 cells collected from 80% to 90% confluent 
cell cultures and immersed in Matrigel/PBS (Methods). Cells were injected near the pump, 24 hours after pump implantation. Xenotransplants of 
MDA231 developed within 10 days in five female mice that were not treated with PJ-34 (untreated mice). Tumors did not develop in five female mice 
treated for 14 days with a slow release from a subcutaneously implanted osmotic pump (Alzet pump). Tumors were not detected in these mice dur-
ing 10 weeks after injection with MDA231 cells and 8 weeks after the treatment with PJ-34. A detailed presentation of this experiment is included in 
Additional data file 1. (c) Kaplan-Meier survival analysis is used for presenting tumor-free survival curves of mice injected with MCF-7 cells and mice 
injected with MDA231 cells, without or after treatment with PJ-34, as described earlier. The significance (log-rank significance test) was P = 0.0253 
for mice injected with MCF-7 cells, and P = 0.0023 for mice injected with MDA231 cells.Available online http://breast-cancer-research.com/content/11/6/R78
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After 10 weeks, we detected tumors in two of the five mice
that were injected with MDA231 cells and treated with PJ-34.
These tumors were of human origin, as indicated by histo-
chemistry (labeling with mouse anti-human mitochondria anti-
body (Millipore/Biotest) applied after blocking ("mouse-on-
mouse"; Vector Labs/Zotal)).
Tumor-free survival curves [18] for mice injected with MCF-7
cells and for mice injected with MDA231 cells are presented
in Figure 6c. The effect of treatment with PJ-34 on tumor-free
survival is indicated, and significance was calculated with the
log-rank significance test [18].
Discussion
Findings indicating that polyADP-ribosylation is required for
spindle formation [19] are in accordance with the observed
G2/M arrest in both normal and malignant dividing cells treated
with the potent PARP inhibitor PJ-34 (Figures 3, 4b, 5b). It is
puzzling how normal cells overcome the G2 arrest while malig-
nant cells die.
G2 arrest could be induced by DNA damage in proliferating
cells [20]. Because of their genomic instability and fast prolif-
eration, malignant cells might be more susceptible to inhibition
of PARP mediated DNA repair than are normal proliferating
cells [13,14]. However, eradication of MCF-7 and MDA231
cells was not shared by other non- phenanthridine-derived
PARP inhibitors, and the examined cell lines MCF-7 and
MDA231 were neither BRCA-deficient cells [21] nor PTEN
(phosphatase and tensin homologue)-deficient cells [22], in
which DNA-repair mechanisms are impaired [15,23].
Other possible mechanisms underlying G2/M arrest implicate
signal-transduction pathways involving p53, p21/WAF1,
cdc25c, cdc2, and suppressed cyclin-B gene expression
[20,24-26]. Stabilization of p21 could promote G2 arrest and
induce cell death [25]. ERK activation also is implicated in G2/
M transition control. Nuclear translocation of cyclin B/Cdc2
complex, which is required for G2/M transition, could be medi-
ated by ERK activation [20]. Other mechanisms involving ERK
activation in G2/M transition control are not fully resolved. They
include autostabilization of the p21cip/cyclin D1 complex
leading to cell-cycle arrest, and mechanisms promoting degra-
dation of cyclin-dependent inhibitors such as p27kip1 [26-
31]. Various impairments in some of these regulatory mecha-
nisms were detected in human cancer cell types.
Numerous primary human tumors and derived cell lines display
a constitutive activation of ERK [8,31-34]. Some of them har-
bor mutations of the Ras protein that render it and the Raf-
MEK-ERK cascade constitutively active [35-37]. Constitutively
activated Raf has been found in many human cancers [35-37].
ERK targets are constitutively activated in B-Raf melanomas,
colon cancer, PC-3 prostate cancer, and pancreatic cancer
cells [37-39]. Growth and proliferation of the human breast
cancer MCF-7 and MDA231 cells are also highly dependent
on ERK activity [40-42].
Blocking the activity of ERK by blocking the Ras/Raf/MEK/
ERK pathway is one of the main targets for human cancer
treatment. However, previous clinical studies showed an insuf-
ficient antitumor activity of MEK inhibitors [39], suggesting
that the MEK/ERK phosphorylation pathway is resilient to dim-
inution of the activity of MEK and can adapt rapidly to maintain
nearly normal ERK activation [39].
The recently disclosed augmentation of ERK activity in the
nucleus by polyADP-ribosylated PARP-1 [3], and the fact that
PARP-1 silencing with targeted siRNA downregulated ERK
phosphorylation in nuclei of both MCF-7 and MDA231 cells
(not shown), urged us to examine PARP inhibitors for their
possible effect on cell proliferation in the absence of DNA-
damaging factors. However, whereas phenanthridine-derived
PARP inhibitors efficiently arrested the cell proliferation of
MCF-7 and MDA231 cancer cells, other potent PARP inhibi-
tors did not cause a similar effect. PARP inhibitor, ABT-888
(benzimidazole-4-carboxamide) hardly affected MCF-7 and
MDA231 cells (not shown), and potent PARP inhibitors effi-
ciently eradicating BRCA mutated breast cancer cells did not
similarly eradicate MCF-7 cells [13,14] and cancer cells not
carrying BRCA mutations [43]. Hence, additional features of
the phenanthridine-derived PARP inhibitors apparently under-
lie their very promising potency to arrest proliferation and
cause cell death in cancer cells lacking mutations that impair
DNA repair, without impairing normal proliferating or quiescent
cells.
Conclusions
Phenanthridine-derived PARP inhibitors possess a promising
potency to arrest proliferation (G2/M arrest) and cause cell
death in MCF-7 and MDA231 human breast cancer cells,
without impairing normal proliferating human epithelial cells,
fibroblasts, or quiescent cells (neurons, cardiomyocytes).
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